BioSpace News Archive

OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13.

Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today announced the presentation of interim data from a first-in-human, Phase 1 study evaluating PRTX007, a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the American Association of Cancer Research (AACR) Annual Meeting.

Asher Biotherapeutics (Asher Bio), today announced preclinical data for AB821, its CD8+ T cell cis-targeted interleukin-21 (IL-21) cytokine, which was designed to promote the function, survival, and reduced exhaustion of CD8+ T cells, and for its cis-targeted interleukin-2 (IL-2) fusion molecules, which were developed to specifically target engineered cells such as CAR-T cells, while exhibiting minimal effects on non-engineered or endogenous cells.

Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, today presented two posters at the American Association for Cancer Research (AACR) Annual Meeting, occurring April 8-13, 2022.

Orphagen Pharmaceuticals Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced a late-breaking presentation of new preclinical data for OR-449 at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13 both virtually and in-person in New Orleans.

Scorpion Therapeutics, Inc. today announced preclinical proof-of-concept data for STX-478.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR, as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data from the dose escalation phase of the phase 1/2a study with the Company’s Innate Cell Engager (ICE®) AFM24 as monotherapy at the Annual Meeting of the American Association of Cancer Research (AACR).

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Ensuring the availability of innovative interventions for people is a shared priority for both the Centers for Medicaid & Medicare Services and the U.S. Food and Drug Administration.